magrolimab   Click here for help

GtoPdb Ligand ID: 12652

Synonyms: Hu5F9-G4
Immunopharmacology Ligand
Compound class: Antibody
Comment: Magrolimab (Hu5F9-G4) is a clinical lead, humanized monoclonal antibody, that binds to and blocks the function of cluster of differentiation 47 (CD47), a 'don't-eat-me' signal that is overexpressed by some cancer cells [1]. CD47-blockade disrupts the CD47-SIRPα anti-phagocytic checkpoint, which induces an immunostimulating effect that promotes macrophage-mediated phagocytosis of tumour cells [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Magrolimab is being developed in several haematologic malignancies and advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03248479 Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Phase 1 Interventional Gilead Sciences
NCT05079230 Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia Phase 3 Interventional Gilead Sciences
NCT04313881 Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Phase 3 Interventional Gilead Sciences
NCT04854499 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma Phase 2 Interventional Gilead Sciences
NCT04958785 Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer Phase 2 Interventional Gilead Sciences
NCT05330429 Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) Phase 2 Interventional Gilead Sciences